Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Regarding the phenotypic classification based on the immunohistochemical expressions of CD10, MUC2 and MUC5AC, the incidence of unclassified type (CD10-, MUC2- and MUC5AC-) was significantly more frequent in the de novo (32%) than CIA (5%) type.
|
31282116 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
High expression of MUC 1 was related to a significantly shorter overall survival, both in the whole series (p = 0.04), while adenocarcinomas positive for MUC 2 tended to have a worse overall survival (p = 0.07).
|
31076280 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The 0-IIa lesion was composed of a tubular structure positive for MUC2, and it was diagnosed as an intestinal phenotype of well differentiated adenocarcinoma.
|
28591047 |
2017 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In the "specimens without polyps or adenocarcinoma" category, high (+) MUC2 positivity was more frequent in HIS than in control.
|
28188751 |
2017 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here, we sought to characterize the expression profile of SOX2 and CDX2 in the sequential alterations of the esophageal mucosa towards adenocarcinoma and compare it with the well-established gastric and intestinal mucin profiles (MUC5AC, MUC6, and MUC2).
|
27766003 |
2016 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Mucinous balls surrounded by mesothelial cells and MUC2-positive adenocarcinoma cells are useful clues in the diagnosis of PMP.Diagn.Cytopathol.2016;44:628-631.
|
27079739 |
2016 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The current study further showed that at the early stage (<3 months) the Muc2 knockout mice spontaneously developed chronic inflammation in colon and rectum, similar pathological features as human colitis; and at the late stage (>3 months) the mice exhibited colorectal cancer, including a unique phenotype of rectal prolapsed (rectal severe inflammation and adenocarcinoma).
|
24941171 |
2014 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Cdx2, mucin (MUC) series (MUC2, MUC5AC and MUC6), p53 and E-cadherin expression in Barrett's esophagus and adenocarcinoma specimens were examined by immunostaining.
|
23382633 |
2013 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
On the other hand, in cases with adenocarcinoma, the expression of MUC2 was seen in 92% of cases, while TF antigen was observed in 84% and 60% of cases as detected by GOS and immunohistochemically respectively.
|
21381504 |
2011 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer?
|
18038313 |
2008 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Compared with microsatellite-stable mucinous carcinoma, microsatellite-unstable mucinous carcinomas were significantly associated with a proximal location, intra- and peritumoral inflammatory cell infiltration, frequent MUC5AC expression, a low incidence of lymph node metastasis and absent hMLH1 protein expression, which is not different to medullary type poorly differentiated adenocarcinoma except for MUC2 expression and age-related occurrence.
|
17316416 |
2007 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Sox2 was found to be transcribed in G and GI-mixed type adenocarcinomas in accordance with MUC5AC and MUC6 expression, while Cdx1 and Cdx2 were up-regulated in GI-mixed and I types along with the expression of MUC2 and villin.
|
15910596 |
2005 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Pancreatic mucinous noncystic (colloid) carcinomas (MNCC) differ from the usual ductal adenocarcinomas in their mucin expression profile and share with many extrapancreatic mucinous carcinomas the expression of MUC2.
|
12808058 |
2003 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In the present work we evaluated, by immunohistochemistry, the presence and the expression of PCNA, p53, HSP60, HSP10 and MUC-2 in a series of nodular hyperplasia, low- and high-grade prostatic intraepithelial lesions and adenocarcinomas.
|
12820390 |
2003 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Short chain fatty acids and colon cancer.
|
12468628 |
2002 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The latter shows a pattern similar to the conventional ductal adenocarcinomas with a loss of MUC2 and a gain of MUC1 and has a greater tendency to metastasize.
|
12210083 |
2002 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In high grade dysplasia and adenocarcinoma there was downregulation of MUC2, MUC3, MUC5AC, and MUC6, but upregulation of MUC1 and MUC4 in half of the specimens examined.
|
11076872 |
2000 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas.
|
11051251 |
2000 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
All but 1 of the 10 metastatic colon adenocarcinomas expressed MUC2, whereas none expressed MUC5AC.
|
10872659 |
2000 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
By contrast, MUC2 was focally expressed in non-dysplastic as well as in dysplastic epithelia and more frequently in well-differentiated adenocarcinoma.
|
10398137 |
1999 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
A total of 40 breast carcinomas (22 of mucinous and 18 of ductal invasive type), 39 ovarian adenocarcinomas (16 mucinous, 23 serous), 47 colorectal carcinomas (25 mucinous and 22 non-mucinous), and 41 pancreatic adenocarcinomas (14 mucinous, 27 non-mucinous) were investigated by immunohistochemistry with the anti-MUC2 monoclonal antibody 4F1 and the expression pattern was ranked.
|
9306958 |
1997 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Western blot analysis of the cell homogenate showed higher expression of MUC2 apomucin and mucin-associated carbohydrate antigens, such as T, Tn and sialyl Tn, with decreased sialyl Le(x) expression in C1a cells compared with HM3.
|
9291818 |
1997 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The alterations of MUC2 expression detected by immunohistochemistry in adenocarcinomas were confirmed on mRNA level.
|
7927933 |
1994 |
Adenoma
|
0.380 |
Biomarker
|
group |
BEFREE |
In the conventional adenoma category, in HIS (versus control), the MUC1 positivity rate was lower, whereas both high (+) MUC2 positivity and high (+) MUC5AC positivity were less frequent.
|
28188751 |
2017 |
Adenoma
|
0.380 |
AlteredExpression
|
group |
BEFREE |
The current study was investigated the expression of MUC2 and TF antigens in patients with adenoma and CRC.
|
21381504 |
2011 |